

19/37,DE/89 (Item 89 from file: 351)

34168 WPI Acc No: 90-221169/29

KRAM Acc No: C90-095459

KRPX Acc No: N90-171481

Monoclonal antibody - has human protooncogene prod. as homologous antigen

Index Terms: MONOCLONAL ANTIBODY; HUMAN PROTO ONCOGENIC PRODUCT HOMOLOGUE ANTIGEN

Patent Assignee: (AJIN ) AJINOMOTO KK; (NICH-) NICHIREI KK

Number of Patents: 001

Patent Family:

CC Number	Kind	Date	Week
JP 2150293	A	900608	9029 (Basic)

Priority Data (CC No Date): JP 88204207 (880817); JP 89177392 (890710)

Abstract (Basic): JP 2150293

(1) Monoclonal antibody where its homologous antigen is human protooncogene @erbB@-2 prod. and (2) hybridoma which produces monoclonal antibody of (1) are claimed.

Specifically claimed are: monoclonal antibody of (1) produced by hybridoma obtd. by cell fusion of immunised animal's antibody producing cell by using human protooncogene @erbB@-2 expression cell as immunogen, and myeloma cell; monoclonal antibody of (1) which belongs to IgM subgroup, reacts to SV-11 cell but does not react to NIH 3T3 cell; monoclonal antibody of (1) which belongs to IgG subgp., reacts to SV11-cell but does not react to NIH 3T3 cell; monoclonal antibody SV2-61; monoclonal antibody SV2-61 gamma; hybridoma SV2-61; and hybridoma SV2-61 gamma.

USE/ADVANTAGE - Monoclonal antibody uses substance which is not previously known, as homologous antigen. It is prepd. at first by using new cell as immunogen. The monoclonal antibody reacts (antigen-antibody reaction) to human C-@erbB@ gene prod. specifically. @ (7pp Dwg.No.0/0)@

Derwent Class: @B04@; @D16@; S03; R16;

Int Pat Class: @A61K-039/39@; @C12N-005/20@; @C12N-015/06@; @C12P-021/08@; @C12R-001/91@; @G01N-033/57@

English Translation of the claims of JP 2-150293:

Application No.: 1-177392

Filing Date: July 10, 1989

Laid Open Date: June 8, 1990 (as JP A 2-150293)

Date of Official Decision to Grant a Patent:

December 16, 1997

Date of Registration: March 27, 1998

Patent Number: 2761543

Patentee: Ajinomoto and Nichirei

Title: Monoclonal antibody against product of human oncogene, and hybridoma producing the same

1. A monoclonal antibody, which is produced by a hybridoma obtained by fusing an antibody-producing cell with a myeloma cell, and a homologous antibody of which is human oncogene erb-2 product, said antibody-producing cell being obtained in animal using a cell expressing human oncogene erb-2 product on its surface as an immunogen.

2. The monoclonal antibody according to claim 1, which belongs to IgM sub-group, and reacts with SV-11 cell but does not react NIH3T3 cell.

3. The monoclonal antibody according to claim 1, which belongs to IgG sub-group, and reacts with SV-11 cell but does not react NIH3T3 cell.

4. The monoclonal antibody according to claim 2, which is produced by a hybridoma deposited as accession No. 10162 to the FRI.

5. The monoclonal antibody according to claim 3, which is produced by a hybridoma deposited as accession No. 10777 to the FRI.

6. A hybridoma, which produces a monoclonal antibody according to any one of claims 1 to 5.

7. The hybridoma according to claim 6, deposited as an accession No. 10162 to the FRI.

To: Genentech, Inc.

June 8, 1998

Page4

8. The hybridoma according to claim 6, deposited as an accession No. 10777 to the FRI.

Note: Name of FRI has been changed to the National Institute of Bioscience and Human-Technology (NIBH) in 1993.